Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A Mosquito Bite with Devastating Complications in an Immunocompromised Patient.

Frietsch JJ, Winkelmann N, Hunstig F, Schnetzke U, Hammersen FJ, Dönicke T, Lenz M, Gras F, Scholl S, Hochhaus A, Hilgendorf I.

Case Rep Oncol. 2019 Jan 4;12(1):22-28. doi: 10.1159/000495878. eCollection 2019 Jan-Apr.

2.

Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies.

Winkelmann N, Schäfer V, Rinke J, Kaiser A, Ernst P, Scholl S, Hochhaus A, Ernst T.

J Cancer Res Clin Oncol. 2017 Dec;143(12):2511-2519. doi: 10.1007/s00432-017-2518-z. Epub 2017 Sep 14.

PMID:
28913558
3.

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.

Rinke J, Müller JP, Blaess MF, Chase A, Meggendorfer M, Schäfer V, Winkelmann N, Haferlach C, Cross NCP, Hochhaus A, Ernst T.

Leukemia. 2017 Sep;31(9):1936-1943. doi: 10.1038/leu.2017.190. Epub 2017 Jun 19.

PMID:
28626218
4.

Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.

Winkelmann N, Desole M, Hilgendorf I, Ernst T, Sayer HG, Kunert C, Mügge LO, Hochhaus A, Scholl S.

J Cancer Res Clin Oncol. 2016 Dec;142(12):2603-2610. Epub 2016 Sep 17.

PMID:
27640002
5.

EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.

Schäfer V, Ernst J, Rinke J, Winkelmann N, Beck JF, Hochhaus A, Gruhn B, Ernst T.

J Cancer Res Clin Oncol. 2016 Jul;142(7):1641-50. doi: 10.1007/s00432-016-2174-8. Epub 2016 May 11.

PMID:
27169594
6.

Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma.

Wentrup R, Winkelmann N, Mitroshkin A, Prager M, Voderholzer W, Schachschal G, Jürgensen C, Büning C.

Gut Liver. 2016 May 23;10(3):470-5. doi: 10.5009/gnl15175.

7.

Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Winkelmann N, Rose-Zerilli M, Forster J, Parry M, Parker A, Gardiner A, Davies Z, Steele AJ, Parker H, Cross NC, Oscier DG, Strefford JC.

Haematologica. 2015 Jun;100(6):e237-9. doi: 10.3324/haematol.2014.120238. Epub 2015 Feb 20. No abstract available.

8.

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.

Schmidt M, Rinke J, Schäfer V, Schnittger S, Kohlmann A, Obstfelder E, Kunert C, Ziermann J, Winkelmann N, Eigendorff E, Haferlach T, Haferlach C, Hochhaus A, Ernst T.

Leukemia. 2014 Dec;28(12):2292-9. doi: 10.1038/leu.2014.272. Epub 2014 Sep 12.

PMID:
25212276
9.

Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.

Fernandez-Mercado M, Pellagatti A, Di Genua C, Larrayoz MJ, Winkelmann N, Aranaz P, Burns A, Schuh A, Calasanz MJ, Cross NC, Boultwood J.

Br J Haematol. 2013 Oct;163(2):235-9. doi: 10.1111/bjh.12491. Epub 2013 Jul 24.

PMID:
23889083
10.

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim DW, Boultwood J, Rossi F, Gaipa G, De Martini GP, di Celle PF, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NC, Gambacorti-Passerini C.

Nat Genet. 2013 Jan;45(1):18-24. doi: 10.1038/ng.2495. Epub 2012 Dec 9.

11.

Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.

Winkelmann N, Hidalgo-Curtis C, Waghorn K, Score J, Dickinson H, Jack A, Ali S, Cross NC.

Leuk Lymphoma. 2013 Jul;54(7):1527-31. doi: 10.3109/10428194.2012.753544. Epub 2013 Jan 28.

PMID:
23186533
12.

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

Oscier DG, Rose-Zerilli MJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J, Parker H, Parker A, Gardiner A, Collins A, Else M, Cross NC, Catovsky D, Strefford JC.

Blood. 2013 Jan 17;121(3):468-75. doi: 10.1182/blood-2012-05-429282. Epub 2012 Oct 18.

13.

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.

Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D, Zoi K, Ernst T, Stegelmann F, Döhner K, Chase A, Cross NC.

Blood. 2012 Feb 2;119(5):1208-13. doi: 10.1182/blood-2011-07-367243. Epub 2011 Nov 3.

14.

Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma.

Winkelmann N, Petersen I, Kiehntopf M, Fricke HJ, Hochhaus A, Wedding U.

J Cancer Res Clin Oncol. 2011 Apr;137(4):733-8. doi: 10.1007/s00432-010-0933-5. Epub 2010 Jul 3.

PMID:
20602238
15.

Determination of the diversity of Rhodopirellula isolates from European seas by multilocus sequence analysis.

Winkelmann N, Jaekel U, Meyer C, Serrano W, Rachel R, Rosselló-Mora R, Harder J.

Appl Environ Microbiol. 2010 Feb;76(3):776-85. doi: 10.1128/AEM.01525-09. Epub 2009 Nov 30.

16.

Chromatin structure and DNA methylation of the IL-4 gene in human T(H)2 cells.

Santangelo S, Cousins DJ, Winkelmann N, Triantaphyllopoulos K, Staynov DZ.

Chromosome Res. 2009;17(4):485-96. doi: 10.1007/s10577-009-9040-3. Epub 2009 Jun 12.

PMID:
19521787
17.

An improved isolation method for attached-living Planctomycetes of the genus Rhodopirellula.

Winkelmann N, Harder J.

J Microbiol Methods. 2009 Jun;77(3):276-84. doi: 10.1016/j.mimet.2009.03.002. Epub 2009 Mar 18.

PMID:
19303037
18.

RAD-51-dependent and -independent roles of a Caenorhabditis elegans BRCA2-related protein during DNA double-strand break repair.

Martin JS, Winkelmann N, Petalcorin MI, McIlwraith MJ, Boulton SJ.

Mol Cell Biol. 2005 Apr;25(8):3127-39.

19.

Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.

Hartwig UF, Winkelmann N, Wehler T, Kreiter S, Schneider PM, Meyer RG, Ullmann AJ, Huber C, Kolbe K, Herr W.

Ann Hematol. 2005 May;84(5):331-8. Epub 2005 Feb 23.

PMID:
15726363
20.
21.

Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation.

Kreiter S, Winkelmann N, Schneider PM, Schuler M, Fischer T, Ullmann AJ, Huber C, Derigs HG, Kolbe K.

Bone Marrow Transplant. 2001 Jul;28(2):157-61.

Supplemental Content

Loading ...
Support Center